Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Researchers at Copenhagen University in Denmark work on a potential coronavirus vaccine. Photo: Thibault Savary/AFP/Getty Images

Scientists around the world have started dozens of clinical trials, on more than 100 drugs, in the hunt to find a product that could attack the new coronavirus. More data will be coming soon.

The big picture: Expectations need to be tempered. A vaccine is likely a long way off, and failures are inevitable. But some experimental treatments, while they still require more research, are showing promise.

Where it stands: There are more than 100 coronavirus drugs and vaccines in development worldwide, according to Umer Raffat, an analyst at Evercore ISI who has been tracking progress. 

  • The coronavirus has become the pharmaceutical world’s top priority, but safety and efficacy haven’t been proven anywhere yet.

A handful of potential treatments are worth paying particular attention to.

  • Remdesivir: This antiviral drug, made by Gilead Sciences, is the furthest along of any potential treatment. It's in six clinical trials, including two late-stage U.S. studies, and new results should come out next month.
  • mRNA-1273: This drug, made by Moderna, is the first vaccine candidate to enter a clinical trial. Moderna’s CEO said the hope is to get into a final study by this fall, but even if the vaccine proves to be effective, there are major questions how a small drugmaker can scale this to billions of people.
  • Hydroxychloroquine has almost become a household name, after President Trump touted the results from a small, imperfect French study. It's a generic drug, already on the marker and made by several companies. Chinese scientists are in the process of studying it further.
  • INO-4800: An experimental vaccine made by U.S. drugmaker Inovio is going to be tested for the first time on 30 U.S. patients next month.
  • Avigan: This influenza treatment, also known as favipiravir and made by Japanese and Chinese companies, has shown “a high degree of safety” among some coronavirus patients, according to Chinese scientists who are testing it.
  • Kevzara: This medication, made by Regeneron and Sanofi, is approved for arthritis and will now be tested in up to 400 U.S. patients in an advanced clinical trial.

Go deeper

U.S. charges 4 Belarus officials with air piracy in journalist's arrest

A Boeing 737-8AS Ryanair passenger planefrom Athens, Greece, that was diverted to Minsk, Belarus, in May. Photo: Petras Malukas/AFP via Getty Images

The Justice Department on Thursday charged four Belarusian government officials with conspiracy to commit aircraft piracy as part of an operation to arrest a dissident Belarusian journalist.

Why it matters: Prosecutors say the officials fabricated a bomb threat aboard a Ryanair flight carrying the journalist Raman Pratasevich last May, forcing it to land in Minsk, Belarus instead.

17 mins ago - World

What Putin's Ukraine options look like

Putin confers with Defense Minister Sergei Shoigu. Photo: Mikhail Svetlov/Getty

The Biden administration is framing Russian escalation in Ukraine as almost a foregone conclusion, but the Russians are still at the table and Vladimir Putin may be seeking concessions from the West rather than a military confrontation with Kyiv.

Driving the news: Secretary of State Tony Blinken, who will meet his Russian counterpart Sergey Lavrov tomorrow in Geneva, contended in a speech Thursday from Berlin that Putin's intentions are clear: "He's laying the groundwork for an invasion because he doesn’t believe Ukraine is a sovereign nation."

Dan Primack, author of Pro Rata
Updated 35 mins ago - Economy & Business

Peloton stock tanks on report of production halt

Illustration: Aïda Amer/Axios

Peloton stock fell by as much as 25% on Thursday, following a CNBC report that the connected fitness company will temporarily halt production on its bikes and treadmills.

Why it matters: Peloton is viewed by many as a proxy for consumer behavior in the pandemic era, as its popularity surged when gyms closed and people wanted to exercise at home.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!